Drug Trial for Preterm Infants (for babies less than 24 hours old)
Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants
(CSR #170975144639) Preterm infants administered weekly Darbe starting within 36 hours of birth and continuing to 35 weeks gestational age will have improved neurocognitive outcome at 22-26 months (with deaths assigned the lowest possible score of 54), compared to placebo recipients.
Children who are newborns (only infants who are 23-28 weeks at birth and who are less than 24 hours of age are eligible).
Let us know how the study team can reach you.
If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email firstname.lastname@example.org and someone will assist you.